ATS GUIDELINES Bundle

Severe Asthma

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link: http://eguideline.guidelinecentral.com/i/592884

Contents of this Issue

Navigation

Page 1 of 15

Key Points Î Severe asthma is defined as asthma that requires treatment with high dose inhaled corticosteroids plus a second controller and/or systemic corticosteroids to prevent it from becoming ''uncontrolled'' or that remains ''uncontrolled'' despite this therapy. (See Tables 1 & 2) Î Severe asthma is a heterogeneous condition consisting of phenotypes such as severe allergic asthma, eosinophilic asthma, neutrophilic asthma, chronic airflow obstruction, recurrent exacerbations and corticosteroid insensitivity. Î The prevalence of severe asthma in adults and children is estimated to be 5–10% of the total asthma population. Î The ATS/ERS Severe Asthma guidelines make recommendations addressing the roles of computed tomography, sputum eosinophils, and exhaled nitric oxide in the diagnosis of severe asthma. (see Table 3) Î The ATS/ERS Severe Asthma guidelines make recommendations addressing the roles of anti-IgE antibody, methotrexate, macrolide antibiotics, anti-fungal agents, and bronchial thermoplasty in the treatment of severe asthma. (see Table 6)

Articles in this issue

view archives of ATS GUIDELINES Bundle - Severe Asthma